CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shaw, R. J.
Right arrow Articles by Jacks, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shaw, R. J.
Right arrow Articles by Jacks, T.

Cell Growth & Differentiation, Vol 9, Issue 4 287-296, Copyright © 1998 by American Association of Cancer Research


ARTICLES

Localization and functional domains of the neurofibromatosis type II tumor suppressor, merlin

RJ Shaw, AI McClatchey and T Jacks
Department of Biology and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge 02139, USA.

The neurofibromatosis type II (NF2) tumor suppressor gene is inactivated in the development of familial and sporadic schwannomas and meningiomas. The encoded protein, merlin, is closely related to ezrin, radixin, and moesin, which are members of the band 4.1 family of membrane/cytoskeletal linker proteins. We have examined the localization and effects of overexpressing epitope-tagged full-length isoforms of merlin as well as amino- and carboxyl-terminal truncations. The full-length and the amino-terminal domain of merlin localize to cortical actin, particularly areas of dynamic actin rearrangements such as membrane ruffles. Furthermore, overexpression of the carboxyl half of merlin induces cell death in NIH3T3 cells. The effect is splice-form specific and is not observed in the context of the full-length molecule. Thus, as has been described for the erzin, radixin, and moesin proteins, the activities of the carboxyl-terminal domain of merlin may be suppressed by the amino-terminal domain.


This article has been cited by other articles:


Home page
Circ. Res.Home page
T. Matsuda, P. Zhai, S. Sciarretta, Y. Zhang, J. I. Jeong, S. Ikeda, J. Park, C.-P. Hsu, B. Tian, D. Pan, et al.
NF2 Activates Hippo Signaling and Promotes Ischemia/Reperfusion Injury in the Heart
Circ. Res., August 19, 2016; 119(5): 596 - 606.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
S. BELTRAMI, R. KIM, and J. GORDON
Neurofibromatosis Type 2 Protein, NF2: An Uncoventional Cell Cycle Regulator
Anticancer Res, January 1, 2013; 33(1): 1 - 11.
[Abstract] [Full Text] [PDF]


Home page
EMBO Rep.Home page
W. Li, J. Cooper, M. A. Karajannis, and F. G. Giancotti
Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus
EMBO Rep., March 1, 2012; 13(3): 204 - 215.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
D. Lallemand, A. L. Saint-Amaux, and M. Giovannini
Tumor-suppression functions of merlin are independent of its role as an organizer of the actin cytoskeleton in Schwann cells
J. Cell Sci., November 15, 2009; 122(22): 4141 - 4149.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
B. K. Cole, M. Curto, A. W. Chan, and A. I. McClatchey
Localization to the Cortical Cytoskeleton Is Necessary for Nf2/Merlin-Dependent Epidermal Growth Factor Receptor Silencing
Mol. Cell. Biol., February 15, 2008; 28(4): 1274 - 1284.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
M. Gronholm, L. Vossebein, C. R. Carlson, J. Kuja-Panula, T. Teesalu, K. Alfthan, A. Vaheri, H. Rauvala, F. W. Herberg, K. Tasken, et al.
Merlin Links to the cAMP Neuronal Signaling Pathway by Anchoring the RI{beta} Subunit of Protein Kinase A
J. Biol. Chem., October 17, 2003; 278(42): 41167 - 41172.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
J. L. Kissil, K. C. Johnson, M. S. Eckman, and T. Jacks
Merlin Phosphorylation by p21-activated Kinase 2 and Effects of Phosphorylation on Merlin Localization
J. Biol. Chem., March 22, 2002; 277(12): 10394 - 10399.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A.-M. Bashour, J.-J. Meng, W. Ip, M. MacCollin, and N. Ratner
The Neurofibromatosis Type 2 Gene Product, merlin, Reverses the F-Actin Cytoskeletal Defects in Primary Human Schwannoma Cells
Mol. Cell. Biol., February 15, 2002; 22(4): 1150 - 1157.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
E. Brault, A. Gautreau, M. Lamarine, I. Callebaut, G. Thomas, and L. Goutebroze
Normal membrane localization and actin association of the NF2 tumor suppressor protein are dependent on folding of its N-terminal domain
J. Cell Sci., May 15, 2001; 114(10): 1901 - 1912.
[Abstract] [PDF]


Home page
Mol. Cell. Biol.Home page
L. Goutebroze, E. Brault, C. Muchardt, J. Camonis, and G. Thomas
Cloning and Characterization of SCHIP-1, a Novel Protein Interacting Specifically with Spliced Isoforms and Naturally Occurring Mutant NF2 Proteins
Mol. Cell. Biol., March 1, 2000; 20(5): 1699 - 1712.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
M. Giovannini, E. Robanus-Maandag, M. Niwa-Kawakita, M. van der Valk, J. M. Woodruff, L. Goutebroze, P. Merel, A. Berns, and G. Thomas
Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein
Genes & Dev., April 15, 1999; 13(8): 978 - 986.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1998 by the American Association of Cancer Research.